Immutep Ltd.

Immutep Ltd. is a biotechnology company specializing in the development of immunotherapeutics for the treatment of cancer and autoimmune diseases. The company's primary focus is on its leading product candidate, eftilagimod alpha, a soluble LAG-3 protein intended to enhance the body’s immune response against tumors. Immutep’s research revolves around Lymphocyte Activation Gene-3 (LAG-3), a promising target for cancer immunotherapy and autoimmune treatment, setting the company apart in the biotech industry. Headquartered in Sydney, Australia, with significant operations in Europe and the United States, Immutep plays a crucial role in the biopharmaceutical sector by pioneering research that aims to harness and modulate the immune system. Through strategic partnerships and collaborations with pharmaceutical giants, Immutep is positioned as a key player in the development of innovative treatments that may revolutionize the management of cancer and autoimmune conditions, reflecting its significance in the global healthcare market.